Diabetes Crisis in Europe: Urgent Public Health and Economic Challenge

By João L. Carapinha

November 12, 2024

A recently published article by Euractiv provides a comprehensive analysis of the escalating diabetes crisis in Europe, and highlights its significant public health implications, economic burdens, and societal challenges associated with this health issue.

Public Health Crisis

The article describes the rising prevalence of diabetes, particularly Type 2 diabetes, as a “tsunami” that threatens to overwhelm healthcare systems. This rise is driven by factors such as obesity, an ageing population, and poor dietary habits.

Economic Burden

The economic impact of diabetes on Europe is substantial. In 2021, diabetes-related expenditure in Europe totalled approximately €170 billion, which is more than the total EU funding committed to Ukraine since the Russian invasion. This expenditure accounts for 19.6% of global diabetes spending.

The average annual cost per person with diabetes in Europe was around €2,760. For example, Switzerland spent nearly €11,600 per person with diabetes, while the UK, France, and Germany spent between €5,200 and €6,000 per person annually.

Prevalence and Mortality

Spain and Portugal have the highest diabetes prevalence rates in Europe, with nearly 15% and 13% of adults diagnosed, respectively. Most other European countries report prevalence rates of around 8-9%.

Czechia had the highest diabetes-related mortality in 2021, with 43.4 deaths per 100,000 population. Mortality rates were notably higher among men than women across Europe.

Lifestyle Factors

The global prevalence of diabetes is projected to surge, reaching 12.2% of the population by 2045. Type 2 diabetes, which accounts for 95% of all diabetes cases, is heavily influenced by age, poor diet, and sedentary lifestyles. Over 30% of the population in many European countries exhibited insufficient physical activity, and soft drink consumption averaged 98 litres per capita in 2022.

Future Projections

The number of adults living with diabetes in Europe is projected to increase from 32 million today to 35 million by 2030. By 2045, it is estimated that 1 in 10 people in the region will have diabetes.

Policy and Interventions

The article emphasizes the need for immediate and coordinated action to mitigate the impact of diabetes. Policies such as the introduction of a sugar-sweetened drinks tax, food reformulation to reduce calories, fat, salt, and sugar content are on the cards. Regulating the marketing of unhealthy food to children are also being considered or implemented in various European countries.

Broader Implications

The economic burden of the diabetes crisis in Europe includes direct medical expenses such as hospitalizations, medications, and outpatient care. It also includes indirect costs – lost productivity and premature mortality. These costs are limiting European economic growth. Thus, the need for a bold vision to address this crisis as Europe works towards creating a true Health Union.

In summary, Europe is confronted with a diabetes crisis, with severe public health and economic consequences. There’s an urgent need for comprehensive policy interventions to tackle this growing health challenge effectively.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.